

**LETTER TO THE EDITOR**


# Comment on: Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination

To the Editor:

We would like to share ideas on the publication “Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination.”<sup>1</sup> The adverse event of new COVID-19 vaccine is an interesting issue. For a case with underlying disease, there might be a possible risk. Thrombocytopenia is a commonly reported adverse event after COVID-19 vaccination and might be associated with automimmunity.<sup>2</sup> For a person with sickle cell disease, the problem of a thrombohemostatic disorder following vaccination is possible. Not only immunopathological process but also change of blood viscosity might be induced. In general, after COVID-19 vaccination, there will be increased blood viscosity that can further result in a thrombohemostatic disorder.<sup>3</sup> In sickle cell anemia, there is background high blood viscosity<sup>4</sup>; hence, there might be an increasing chance for a high blood viscosity problem inducing clot and relative thrombocytopenia.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

Rujittika Mungmunpantipantip<sup>1</sup>   
Viroj Wiwanitkit<sup>2</sup>

<sup>1</sup> Private Academic Consultant, Bangkok, Thailand

<sup>2</sup> Department of Community Medicine, Dr. DY Patil University, Pune, India

## Correspondence

Rujittika Mungmunpantipantip, Private Academic Consultant,  
Bangkok, Thailand.

Email: [rujittika@gmail.com](mailto:rujittika@gmail.com)

## ORCID

Rujittika Mungmunpantipantip  <https://orcid.org/0000-0003-0078-7897>

## REFERENCES

1. Underdown MJ, Nuss R. Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination. *Pediatr Blood Cancer*. 2021:e29271. <https://doi.org/10.1002/pbc.29271>. Online ahead of print.
2. Kragholm K, Sessa M, Mulvad T, et al. Thrombocytopenia after COVID-19 vaccination. *J Autoimmun*. 2021;123:102712. <https://doi.org/10.1016/j.jaut.2021.102712>. Online ahead of print.
3. Joob B, Wiwanitkit V. Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19. *Clin Appl Thromb Hemost*. 2021;27. <https://doi.org/10.1177/10760296211020833>.
4. Kucukal E, Man Y, Hill A, et al. Whole blood viscosity and red blood cell adhesion: potential biomarkers for targeted and curative therapies in sickle cell disease. *Am J Hematol*. 2020;95(11):1246-1256.